A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above
Phase 2 – studying effectiveness and dosage
Conditions:
Recurrence of Clostridioides difficile Infection
Sponsor: AstraZeneca AB
trial.available_in:
БГ
Overview
Trial status: Authorised
Sustained clinical cure (ie, achievement of initial clinical cure + no recurrent C. difficile infection)
First occurrence of recurrent C. difficile infection
Description
Sustained clinical cure (ie, achievement of initial clinical cure + no recurrent C. difficile infection)
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 122 participants
БГ